Equal benefits to our residential courses, without the travel.View Courses
All our courses. 12 months access. One flat fee.More Information
Happening 10th - 12th November 2020. Full programme available now.View Now
CVMP adopts concept paper on environmental risk assessment for parasiticide veterinary medicinal products used in companion animals CVMP opinions on veterinary medicinal products
Note: This notice should be read in conjunction with Q8 and Q9 from the good clinical practice (GCP) Q&As published on the EMA website: https://www.ema.europa.eu/en/human-regulatory/research-development/compliance/good-clinicalpractice/qa-good-clinical-practice-gcp
Today, the European Commission has published guidance to ensure that clinical trials can continue taking place in the EU during the COVID-19 pandemic.....
The European Parliament and Council have approved a proposal to delay the full implementation of the Medical Device Regulation 2017/745 (MDR) for one year to 26 May 2021. This means that the full applicability of the MDR will fall outside of the transition period agreed with the EU.
The COVID-19 pandemic has significantly impacted health research as it has every aspect of our lives. In this bulletin we pull together information about the special research governance arrangements currently in place to help tackle the pandemic. Many of these arrangements will be temporary.
These temporary good manufacturing practice (GMP) flexibilities will be allowed to address the current exceptional circumstances
The European Commission, EMA and the national competent authorities have agreed a series of measures to mitigate the impact of disruptions caused by COVID-19 on the conduct of inspections of manufacturing facilities or other sites relevant for medicinal products in the European Union.
The MHRA GPvP inspectorate recently published their latest inspection metrics for the period from April 2018 to March 2019. The full metrics report is available on GOV.UK.
The ICH MedDRA Management Committee has decided to provide the new COVID-19 terms within the MedDRA dictionary in a very expedited fashion, given the current very exceptional time with the COVID-19 pandemic demanding flexible approaches to ensure that any scientific and medical information from the COVID-19 outbreak can be captured, shared and analysed appropriately.
The European Commission, EMA and the European medicines regulatory network have developed a question-and-answer (Q&A) document to provide guidance to stakeholders on adaptations to the regulatory framework to address challenges arising from the COVID-19 pandemic, with a particular focus on crucial medicines for use in COVID-19 patients.